GSK plc (GLAXF)

19,85 0,00 (0,00%) Alla chiusura: 09:50AM EDT

GSK plc

980 Great West Road
Middlesex
Brentford TW8 9GS
United Kingdom
44 20 8047 5000
https://www.gsk.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 70.212

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Emma Natasha Walmsley	CEO & Director	6,72M	67,17M	1969
Ms. Julie Belita Brown	CFO & Executive Director	6,41M	N/D	1962
Ms. Shobie Ramakrishnan	Chief Digital & Technology Officer	N/D	N/D	1971
Mr. Tony Wood	Chief Scientific Officer and Head of R&D	N/D	N/D	N/D
Ms. Sarah Elton-Farr	Head of Investor Relations	N/D	N/D	N/D
Mr. James Ford	Senior VP & Group General Counsel of Legal & Compliance	N/D	N/D	N/D
Ms. Sally Jackson	Senior Vice President of Global Communications & CEO Office	N/D	N/D	N/D
Mr. David Simon Redfern BSc (Hons), CA	President of Corporate Development	N/D	N/D	1966
Ms. Diana Conrad	Chief People Officer	N/D	N/D	N/D
Mr. Philip C. Thomson	President of Global Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di GSK plc al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 7; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.